Ligand id: 6886

Name: denosumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: denosumab

1. Boyle WJ, Martin FH, Corvalan JR, Davis CG. (2008)
Immmunoglobulin which prevents binding of osteoprotegerin ligand (OPGL) to osteoclast differentiation and activation receptor (ODAR) for treatment and prevention of bone, inflammatory, arthritic and autoimmune disorders.
Patent number: US7364736. Assignee: Amgen Inc.. Priority date: 26/06/2001. Publication date: 29/04/2008.
2. Coleman RE. (2006)
Clinical features of metastatic bone disease and risk of skeletal morbidity.
Clin. Cancer Res., 12 (20 Pt 2): 6243s-6249s. [PMID:17062708]
3. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH et al.. (2006)
Denosumab in postmenopausal women with low bone mineral density.
N. Engl. J. Med., 354 (8): 821-31. [PMID:16495394]
4. Stewart AF. (2005)
Clinical practice. Hypercalcemia associated with cancer.
N. Engl. J. Med., 352 (4): 373-9. [PMID:15673803]